The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Prevalence of RET Mutations in Lung and Thyroid Cancers

Alexander E. Drilon, MD
Published Online:4:40 PM, Fri December 28, 2018

Alexander E. Drilon, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the prevalence of RET fusions and mutations in patients with cancer, including lung and thyroid cancers.

In lung cancer, or more specifically non–small cell lung cancer, where there are about 200,000 cases every year, RET mutations affect up to 2% of the population. In papillary thyroid cancer, RET mutations are found in 10% to 20% of patients.

In medullary thyroid cancer, RET mutations are seen in a majority of these patients. Overall, Drilon says this is a sizable population.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.